Teligent, Inc. Named to Deloitte's 2015 Technology Fast 500

Nov 13, 2015, 10:09 ET from Teligent, Inc.

BUENA, N.J., Nov. 13, 2015 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced that it has been named to the No. 227 position on the elite listing of Deloitte's 2015 Technology Fast 500™, which ranks the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2011 to 2014, and Teligent, Inc. grew by 332 percent during this period. The company also appeared on the Fast 500 list last year.

"We are honored to receive this level of recognition from Deloitte, and thank the company for recognizing Teligent's success," said Jason Grenfell-Gardner, Teligent's President and CEO.  "Our team continues to execute year over year.  Teligent now sells both specialty generic topical and injectable prescription drugs in the United States, and our long-term vision continues to focus on the creation of a diversified product portfolio, built around our topical, injectable, complex and ophthalmic, or TICO, strategy."

About Deloitte's 2015 Technology Fast 500™

Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2011 to 2014.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years and be headquartered within North America.

About Teligent, Inc.

Teligent, Inc., is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.

Forward Looking Statements

This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "believe," "target," "estimated," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as updated by Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Actual results may differ materially from these expectations. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in and the impact of global political, economic, business, competitive, market, regulatory and other factors; and our inability to complete successfully future product acquisitions.  We assume no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Contact:

Jenniffer Collins


Teligent, Inc.


(856) 697-4379


www.teligent.com

Logo - http://photos.prnewswire.com/prnh/20151113/287129LOGO

 

SOURCE Teligent, Inc.



RELATED LINKS

http://www.teligent.com
http://www.teligent.com